Opioid Use Disorder Market To Reach $10.25 Billion By 2030

Opioid Use Disorder Market Growth & Trends

The global opioid use disorder market size is expected to reach USD 10.25 billion by 2030, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 11.65% from 2024 to 2030. Rising opioid epidemic and growing government initiatives to combat the crisis are likely to propel market growth. In addition, growing commercialization of novel products is further anticipated to drive growth. In 2018, about 2.9 million people aged 15 or above were suffering from this disorder in the U.S. In 2016, according to the National Survey on Drug Use and Health (NSDUH), in the U.S., around 11.5 million people had abused prescription opioids in the earlier year and more than 2 million were addicted to prescribed drugs.

According to the CDC, around 130 Americans die every day due to the opioid overdose and the U.S. government has designated this as a public health emergency.For patients wanting to overcome their addiction, adherence to a Medication-assisted Treatment (MAT) can reduce the withdrawal symptoms and cut the risk of death by half. Three U.S. FDA-approved MAT options are buprenorphine, methadone, and naltrexone. They are available in numerous dosages and formulations, with daily oral buprenorphine as the standard of care.

To combat the opioid crisis, several measures have been undertaken in recent years. For instance, in 2016, CDC clinical practice guidelines for prescribing these drugs for chronic pain were issued and new American Society of Addiction Medicine (ASAM) National Practice Guidelines was adopted in 2015 to improve standard of care. Furthermore, in 2016, the U.S. FDA announced plans to overhaul its regulations for abuse-deterrent opioids, enhance safety labeling, and re-examine the risk-benefit paradigm of their use.

 Request a free sample copy or view report summary: Opioid Use Disorder Market Report

Opioid Use Disorder Market Report Highlights

• Buprenorphine led the market and accounted for 55.94% of the global revenue in 2023 due to its effective dual action as a partial opioid agonist, which helps alleviate withdrawal symptoms and cravings while minimizing euphoria and misuse risk.

• The injectable segment dominated the market and accounted for 55.79% of the global revenue in 2023. Extended release injectables, like Vivitrol (naltrexone) and Sublocade (buprenorphine), offer prolonged, steady drug delivery, improving adherence and reducing the risk of relapse.

• Hospital pharmacies dominated the market with a market share of 48.27% in 2023 due to their integral role in managing complex and severe cases.

• North America opioid use disorder market accounted for 69.18% share in 2023 due to several key factors. The region has the highest prevalence of OUD, which drives significant demand for treatment solutions.

Opioid Use Disorder Market Segmentation

Grand View Research has segmented the global opioid use disorder market on the basis of drug, route of administration, distribution channel and region:

Opioid Use Disorder Drug Outlook (Revenue, USD Million, 2018 - 2030)

• Naltrexone

• Buprenorphine

  • BELBUCA

  • Sublocade

  • Suboxone

  • Zubsolv

  • Others

• Methadone

• Others

Opioid Use Disorder Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Oral Administration

• Injectable Administration

• Others

Opioid Use Disorder Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Retail Pharmacies

• Others

Opioid Use Disorder Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • Kuwait

  • UAE

List of Key Players of Opioid Use Disorder Market

• Indivior PLC

• Teva Pharmaceutical Industries, Ltd.

• Pfizer, Inc.

• Collegium Pharmaceutical (BioDelivery Sciences International, Inc.)

• Alkermes, Inc.

• Orexo US, Inc. (a part of Orexo AB)

• Titan Pharmaceuticals, Inc.

• Omeros Corporation

• Camurus AB

• Hikma Pharmaceuticals PLC